BACE-1 inhibition prevents the ?-secretase inhibitor evoked A? rise in human neuroblastoma SH-SY5Y cells.
Ontology highlight
ABSTRACT: BACKGROUND: Accumulation of amyloid ?-peptide (A?) in the plaques is one of the major pathological features in Alzheimer's disease (AD). Sequential cleavage of amyloid precursor protein (APP) by ?-site APP cleaving enzyme 1 (BACE-1) and ?-secretase results in the formation of A? peptides. Preventing A? formation is believed to attenuate AD progression and BACE-1 and ?-secretase are thus attractive targets for AD drug development. METHODS: Combining BACE-1 and ?-secretase inhibition on A? secretion from human neuroblastoma SH-SY5Y cells was evaluated in this study. Secreted A?40 and A?42 levels were measured from SH-SY5Y cells stably transfected with APPwt or APPswe genes. A selective BACE inhibitor and the ?-secretase inhibitor LY450139 (semagacestat) were used to inhibit respective secretase. RESULTS: LY450139 increased A?40 and A?42 secretion from SH-SY5Y APPwt cells at low concentrations (by 60% at 3 nM) followed by subsequent inhibition at higher concentrations (IC(50) 90 nM). Washout studies showed that the A? increase evoked by 3 nM LY450139 was not due to enhanced cleavage following substrate accumulation but rather to activation of A? formation. By contrast, LY450139 inhibited A? formation from SH-SY5Y APPswe in a monophasic manner (IC(50) 18 nM). The BACE inhibitor per se inhibited A? secretion from both SH-SY5Y APPwt and SH-SY5Y APPswe cells with IC(50)s ranging between 7 - 18 nM and also prevented the increased A? secretion evoked by 3 nM LY450139. Combining the BACE inhibitor with higher inhibitory concentrations of LY450139 failed to demonstrate any clear additive or synergistic effects. CONCLUSION: BACE-1 inhibition attenuates the A? increase evoked by LY450139 while not providing any obvious synergistic effects on LY450139-mediated inhibition.
SUBMITTER: Jamsa A
PROVIDER: S-EPMC3217850 | biostudies-literature | 2011
REPOSITORIES: biostudies-literature
ACCESS DATA